Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) EBT Margin (2016 - 2023)

Historic EBT Margin for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to 31551.45%.

  • Spyre Therapeutics' EBT Margin fell 279812100.0% to 31551.45% in Q2 2023 from the same period last year, while for Mar 2024 it was 52933.58%, marking a year-over-year decrease of 462383800.0%. This contributed to the annual value of 38241.08% for FY2023, which is 346364900.0% down from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' EBT Margin is 31551.45%, which was down 279812100.0% from 9322.22% recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' EBT Margin registered a high of 56.15% during Q2 2021, and its lowest value of 31551.45% during Q2 2023.
  • Its 3-year average for EBT Margin is 7644.89%, with a median of 3570.24% in 2022.
  • In the last 5 years, Spyre Therapeutics' EBT Margin tumbled by -35140900bps in 2022 and then crashed by -279812100bps in 2023.
  • Quarter analysis of 3 years shows Spyre Therapeutics' EBT Margin stood at 560.46% in 2021, then tumbled by -1895bps to 11180.95% in 2022, then plummeted by -182bps to 31551.45% in 2023.
  • Its EBT Margin stands at 31551.45% for Q2 2023, versus 9322.22% for Q1 2023 and 11180.95% for Q4 2022.